Back to Top
Go Back
Journal Photo for Leukemia & Lymphoma
Peer reviewed only Open Access

Leukemia & Lymphoma (L&L)

Publisher : Taylor & Francis
Leukemia & Lymphoma disease biology ethics and epidemiology
Claim Your Journal Get PRC Visit Website
e-ISSN 1029-2403
p-ISSN 1042-8194
Issue Frequency Monthly
Impact Factor 2.2
Est. Year 1989
Mobile 4402080520500
DOI YES
Country United Kingdom
Language English
APC YES
Impact Factor Assignee GOOGLE SCHOLAR
Email apol@cc.huji.ac.il

Journal Descriptions

Leukemia & Lymphoma is an international peer reviewed journal that publishes research on all aspects of hematological malignancies. The journal aims to address the needs of physicians and scientists interested in clinical, translational, laboratory and basic science research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders. Leukemia & Lymphoma covers from clinical and clinico-pathological investigations to fundamental research in the following topics: disease biology mechanisms of action of novel agents development of combination chemotherapy pharmacology and pharmacogenomics ethics and epidemiology

Leukemia & Lymphoma (L&L) is :-

  • International, Peer-Reviewed, Open Access, Refereed, Leukemia & Lymphoma, disease biology, ethics and epidemiology, pharmacology and pharmacogenomics, mechanisms of action of novel agents, unique clinical observations, review articles, letters to the editor , Online or Print , Monthly Journal

  • UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1042-8194, E-ISSN: 1029-2403, Established: 1989, Impact Factor: 2.2
  • Provides Crossref DOI

  • Indexed in: Scopus, WoS

  • Not indexed in DOAJ, PubMed, UGC CARE

Indexing

Publications of L&L

Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysisFootnote‡
Zahra Mahmoudjafari April, 2025
Fixed-treatment duration glofitamab and treat-to-progression epcoritamab are approved in the US for diffuse large B-cell lymphoma (DLBCL) after ≥2 prior therapies. An economic model was de...
Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma
Zhuxia Jia April, 2025
Relapsed refractory primary central nervous system lymphoma (R/R PCNSL) has no recognized optimal therapy due to its grave prognosis and high mortality. This report describes a 69-year-old p...
The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis
Marek Trneny March, 2025
Symptoms of lymphomas include peripheral lymphadenopathy, B-symptoms, and other organ-specific symptoms; however, data on initial symptoms incidence in diffuse large B-cell lymphoma (DLBCL) ...
Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation
Linda Fogelstrand March, 2025
In acute myeloid leukemia with NPM1 mutation, analysis of measurable residual disease (MRD) with reverse transcription quantitative polymerase chain reaction (RT-qPCR) is recommended for res...
Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymp...
Nitin Jain May, 2025
This study described real-world treatment patterns and outcomes among patients with CLL/SLL in the post-cBTKi setting. Included were patients who received at least one cBTKi and subsequent l...
Allogeneic stem cell transplantation for MDS—clinical issues, choosing preparative regimens and outcome
Georg-Nikolaus Franke March, 2025
Despite the vast heterogeneity of myelodysplastic neoplasm (MDS), treatment options are limited and an allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curativ...
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors
Bjørn Tore March, 2025
Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy, driven by the pathognomonic oncogenic fusion protein BCR::ABL1. Tyrosine kinase inhibitors (TKIs) targeting ABL1 have ...
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-c...
Steven M February, 2025
In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH]...
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia...
Fabian Lang February, 2025
Imatinib (IMA) plus chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) is established treatment for Philadelphia chromosome positive (Ph+) acute lymphoblastic leuke...
Indolent lymphoma: addressing the needs of survivors
Stephen Opat January, 2025
Over the past two decades, there has been a continuous improvement in outcome for patients with indolent lymphoma (iNHL) resulting in a gradual accumulation of survivors. While life expectan...